Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation

Figure 1 Extended progression-free survival and overall survival in the dexamethasone 40 mg group and dexamethasone 20 mg group. A: K-M curve analysis of accumulated progression-free survival (PFS). The median PFS for all patients was 37.25 (95%CI: 24.98-39.52) mo in the dexamethasone (DXM) 40 mg group and 38.17 (95%CI: 35.18-41.15) mo in the DXM 20 mg group (P = 0.171). The data revealed no significant difference in PFS between the two groups. The comparison of the PFS between the two groups was determined by the K-M curves and the log-rank test. P < 0.05 was considered a statistically significant difference; B: K-M curve analysis of accumulated overall survival (OS). The median survival time of OS was 50.78 (95%CI: 46.66-54.91) mo in the DXM 40 mg group while 51.69 (95%CI: 47.31-56.07) mo in the DXM 20 mg group (P = 0.171). No differences were noted between the two groups with regard to the OS. The comparison of the OS between the groups was determined by the K-M curves and the log-rank test. P < 0.05 was considered for significant differences.